News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pfizer Inc. (PFE) Mergers And Budget Cuts Hurt Cancer R&D



8/20/2014 7:02:44 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

At Pfizer PFE +0.35%’s second quarter 2014 earnings call, Ms. Jami Rubin, an industry analyst for Goldman Sachs, posed Pfizer CEO, Ian Read, the following question. “And then, I don’t know if Mikael Dolsten is on the call, but just a question on business development, analyzing, outlicensing activity. We’ve seen recently a couple of high profile outlicensing deals, tremelimumab to AstraZeneca (AZN), neratinib to Puma and regrettably, those look like very unfortunate decisions. And just, Ian, are you looking internally? Are you pleased with the team that you have in place who are in charge with making these critical decisions? Thanks very much.”

Hey, check out all the research scientist jobs. Post your resume today!

Read at Forbes


comments powered by Disqus
Forbes
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES